Dossier assessment

Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-66
Last updated

Report documents

  1. Extract of dossier assessment

    Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 584 kB, EN, not accessible
  2. Dossier assessment

    Axicabtagene ciloleucel (diffuse large B-cell lymphoma, second line) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 886 kB, DE, not accessible

Dossier assessment

Indication:

Adults with diffuse large B-cell lymphoma or high-grade B-cell lymphoma that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy

Result of dossier assessment:
  • If high-dose therapy is an option: added benefit not proven
  • If high-dose therapy is not an option: added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2023-12-21 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A23-66
Commission
Commission awarded on 30.06.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

Connected Projects

  1. Dossier assessment

    Axicabtagene ciloleucel (follicular lymphoma) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-63
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Axicabtagene ciloleucel (B-cell lymphoma PMBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G18-19
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Axicabtagene ciloleucel (B-cell lymphoma DLBCL) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G18-18
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Axicabtagene ciloleucel (DLBCL and PMBCL, third line) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-65
    Last updated

    Status: Commission completed

  5. Addendum

    Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Addendum to Commission A23-66

    Project no.
    A23-106
    Last updated

    Status: Commission completed

  6. Dossier assessment

    Axicabtagene ciloleucel (DLBCL and HGBL, second line) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A24-71
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form